| 27/08/26 | 07:00:00 | 27 Aug 2026 | | hVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health markets | GNW |
| 29/09/22 | 09:30:01 | 29 Sept 2022 | | Director dealings | RNS |
| 27/09/22 | 07:00:12 | 27 Sept 2022 | | Upcoming Scientific Presentations | RNS |
| 15/09/22 | 07:00:08 | 15 Sept 2022 | | Comment regarding press speculation | RNS |
| 08/09/22 | 07:01:05 | 8 Sept 2022 | | Interim results and trading update | RNS |
| 08/09/22 | 07:00:15 | 8 Sept 2022 | | Intention to change name to hVIVO plc | RNS |
| 01/09/22 | 07:20:24 | 1 Sept 2022 | | CAP accreditation | RNS |
| 25/08/22 | 07:00:04 | 25 Aug 2022 | | Notice of results | RNS |
| 22/08/22 | 07:00:05 | 22 Aug 2022 | | £10.4m contract with existing Big Pharma client | RNS |
| 04/08/22 | 07:00:07 | 4 Aug 2022 | | £6.2m Influenza human challenge study contract | RNS |
| 05/07/22 | 13:17:35 | 5 Jul 2022 | | Result of AGM | RNS |
| 30/06/22 | 07:00:07 | 30 Jun 2022 | | Omicron human challenge model | RNS |
| 14/06/22 | 07:00:03 | 14 Jun 2022 | | £7.2m RSV human challenge study contract | RNS |
| 10/06/22 | 12:13:37 | 10 Jun 2022 | | Board appointment amendment | RNS |
| 10/06/22 | 12:00:04 | 10 Jun 2022 | | Annual Report and Notice of AGM | RNS |
| 08/06/22 | 07:00:11 | 8 Jun 2022 | | Board appointment | RNS |
| 07/06/22 | 09:05:45 | 7 Jun 2022 | | Second Price Monitoring Extn | RNS |
| 07/06/22 | 09:00:23 | 7 Jun 2022 | | Price Monitoring Extension | RNS |
| 07/06/22 | 07:00:07 | 7 Jun 2022 | | Final results | RNS |
| 01/06/22 | 07:00:07 | 1 Jun 2022 | | GBP14.7m influenza contract signed | RNS |
| 26/05/22 | 07:00:07 | 26 May 2022 | | Completion of Nominated Adviser due diligence | RNS |
| 24/05/22 | 07:00:14 | 24 May 2022 | | Notice of results | RNS |
| 18/05/22 | 07:00:05 | 18 May 2022 | | £7.3m Influenza human challenge study contract win | RNS |
| 12/05/22 | 07:00:08 | 12 May 2022 | | Wellcome publication | RNS |
| 05/05/22 | 07:00:04 | 5 May 2022 | | Vaccine field study contract | RNS |
| 04/05/22 | 07:00:04 | 4 May 2022 | | Challenge virus manufacturing contract | RNS |
| 04/05/22 | 07:00:04 | 4 May 2022 | | Comment re: speculation | RNS |
| 28/04/22 | 07:00:13 | 28 Apr 2022 | | Appointment of Nominated Adviser and Joint Broker | RNS |
| 13/04/22 | 07:00:12 | 13 Apr 2022 | | Proposal to Distribution in Specie Shareholders | RNS |
| 12/04/22 | 12:00:05 | 12 Apr 2022 | | Presentation at World Vaccine Congress | RNS |
| 06/04/22 | 16:35:50 | 6 Apr 2022 | | Price Monitoring Extension | RNS |
| 06/04/22 | 14:05:54 | 6 Apr 2022 | | Second Price Monitoring Extn | RNS |
| 06/04/22 | 14:01:03 | 6 Apr 2022 | | Price Monitoring Extension | RNS |
| 06/04/22 | 11:05:55 | 6 Apr 2022 | | Second Price Monitoring Extn | RNS |
| 06/04/22 | 11:00:52 | 6 Apr 2022 | | Price Monitoring Extension | RNS |
| 31/03/22 | 10:05:21 | 31 Mar 2022 | | Characterisation Study results in Nature Medicine | RNS |
| 25/03/22 | 07:00:06 | 25 Mar 2022 | | £5m RSV human challenge study contract win | RNS |
| 09/03/22 | 16:41:57 | 9 Mar 2022 | | Second Price Monitoring Extn | RNS |
| 09/03/22 | 16:37:03 | 9 Mar 2022 | | Price Monitoring Extension | RNS |
| 08/03/22 | 07:00:05 | 8 Mar 2022 | | Trading Update and screening facilities expansion | RNS |
| 07/03/22 | 14:06:15 | 7 Mar 2022 | | Second Price Monitoring Extn | RNS |
| 07/03/22 | 14:00:55 | 7 Mar 2022 | | Price Monitoring Extension | RNS |
| 07/03/22 | 11:06:09 | 7 Mar 2022 | | Second Price Monitoring Extn | RNS |
| 07/03/22 | 11:00:37 | 7 Mar 2022 | | Price Monitoring Extension | RNS |
| 02/03/22 | 07:00:08 | 2 Mar 2022 | | Investor Presentations | RNS |
| 24/02/22 | 07:00:05 | 24 Feb 2022 | | CEO Appointment | RNS |
| 22/02/22 | 07:00:11 | 22 Feb 2022 | | FDA Breakthrough Designation for Big Pharma RSV | RNS |
| 17/02/22 | 12:05:04 | 17 Feb 2022 | | Positive results from RSV Human Challenge Study | RNS |
| 14/02/22 | 07:00:07 | 14 Feb 2022 | | Launch of STRiVE project | RNS |
| 02/02/22 | 07:00:09 | 2 Feb 2022 | | World’s first COVID-19 Characterisation Study | RNS |
